Specialty and super-specialty medicine platform MrMed is expanding its infrastructure in Bengaluru, one of its top two revenue markets, as part of efforts to improve access to critical care medicines, expand last-mile reach, and strengthen supply consistency across a key demand centre.
At the centre of this expansion is a new storage and distribution hub in Central Bengaluru, an 850 sq ft facility located to support dispatch across the city, including areas that have historically had limited access to specialty medicines. Complementing this is MrMed’s 2,000+ sq ft Bengaluru office, which oversees operations for the city hub and coordinates fulfilment, supply, and service workflows across the country. Together, these reflect the company’s omnichannel model, combining its digital platform with physical infrastructure.
The development also includes sourcing partnerships with local distributors and manufacturers, as well as updates to order processing, billing, and dispatch systems, along with last-mile delivery operations. These changes have enabled MrMed to offer 24-hour delivery across approximately 110 pincodes (560001 to 562162), covering a large part of its catalogue — including oncology drugs, immunosuppressants, and GLP-1 therapies such as semaglutide and tirzepatide.
Devashish Singh, Co-Founder and CEO, MrMed said, “Bengaluru is one of our largest target markets, which makes it a starting point for this level of investment. The operational focus has been on maintaining consistency across the order lifecycle, from availability to last-mile delivery. The company plans to replicate this model in other cities.”
The company is working to extend this model to Delhi and Chennai, followed by Guwahati, Mumbai, and Hyderabad. It expects to achieve full geographic coverage within Bengaluru over the next one to two months.